Renaissance Technologies LLC Acquires 68,100 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Renaissance Technologies LLC lifted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 106.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 131,899 shares of the company’s stock after buying an additional 68,100 shares during the period. Renaissance Technologies LLC owned about 0.40% of TransMedics Group worth $19,867,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in TransMedics Group during the first quarter valued at approximately $35,000. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group during the 2nd quarter worth approximately $47,000. J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC grew its stake in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after buying an additional 93 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in TransMedics Group during the first quarter worth $201,000. Institutional investors own 99.67% of the company’s stock.

Insider Activity

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,948,714.31. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $145.17, for a total transaction of $1,252,091.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at approximately $8,948,714.31. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James R. Tobin sold 20,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $159.33, for a total value of $3,186,600.00. Following the completion of the transaction, the director now directly owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,247 shares of company stock worth $9,650,880. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Down 0.6 %

TMDX stock opened at $165.00 on Friday. The business’s fifty day moving average price is $155.65 and its two-hundred day moving average price is $128.98. The stock has a market capitalization of $5.43 billion, a price-to-earnings ratio of -485.29 and a beta of 1.99. TransMedics Group, Inc. has a fifty-two week low of $36.42 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to analysts’ expectations of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The business’s revenue was up 117.7% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.03) EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on TMDX. TD Cowen increased their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, June 7th. Oppenheimer lifted their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Piper Sandler upped their price objective on TransMedics Group from $170.00 to $180.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Stephens lifted their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Needham & Company LLC initiated coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $171.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.